This is a summary of the European public assessment report (EPAR) for Vimizim. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vimizim. For practical information about using Vimizim, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.
Therapeutic Area (MeSH)
ATC Code
A16AB12
ATC Item
elosulfase alfa
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| recombinant human n-acetylgalactosamine-6-sulfatase | N/A | 依洛硫酸酯酶α |
EMA Name
Vimizim
Medicine Name
Vimizim
Aliases
N/ANo risk management plan link.
